Table 1 CSPG4 pre-clinical and clinical studies cited in the text
From: CSPG4: a prototype oncoantigen for translational immunotherapy studies
References | Cancer type | Methods/therapy | Study phase | Principal evidences |
|---|---|---|---|---|
Burns et al. [86] | Melanoma | CAR-T cells generated from mAb 225.28S | Pre-clinical, in vitro | CAR-T cells are reactive against CSPG4-expressing cells and explanted human melanomas |
Geldres et al. [85] | Melanoma, HNSCC, BC | CAR-T cells generated from mAb 763.74 | Pre-clinical, in vitro and in vivo | CAR-T cells are cytotoxic against a variety of CSPG4-expressing cells and inhibit tumor growth |
Beard et al. [87] | GB, mesothelioma, BC, osteosarcoma, melanoma, GB-derived CIC | CAR-T cells generated from mAb 225.28S, TP41.2, 149.53 and G71.1 | Pre-clinical, in vitro | CAR-T cells demonstrate cytokine secretion and cytolytic function |
Schmidt et al. [89] | Melanoma | CAR-T cells generated with 61scFv | Pre-clinical, in vitro and in vivo | CAR-T cells specific for CD20+CSPG4+ cells induce tumor eradication through targeted elimination |
Melanoma | CD4+Â T cell isolated from healthy donors and patients | Pre-clinical, in vitro | Identification of CSPG4 peptide-specific CD4+ T cells reactive against melanoma cells | |
Rivera et al. [45] | Mesothelioma | mAb TP41.2 | Pre-clinical, in vitro and in vivo | mAb treatment inhibits adhesion, motility, invasiveness of cancer cells and tumor growth |
Wang et al. [46] | TNBC | mAb 225.28 | Pre-clinical, in vitro and in vivo | mAb treatment inhibits adhesion and migration of cancer cells and tumor recurrences/metastasis |
Poli et al. [95] | GB | Combinatorial treatment with mAb9.2.27 and NK cells | Pre-clinical, in vivo | Combination treatment inhibits tumor growth through immunological mechanisms |
de Bruyn et al. [98] | Melanoma | Bifunctional fusion protein between mAb 9.2.27 and soluble human TRAIL | Pre-clinical, in vitro and in vivo | Bifunctional fusion protein induces the apoptosis of cancer cells and the inhibition of tumor growth |
Bluemel et al. [99] | human-CSPG4 transected CHO cells | Different mAb for the generation of CSPG4/CD3-bispecific antibodies (BiTE) | Pre-clinical, in vitro | BiTE antibodies redirect the lysis of CSPG4+ cells according to the position of epitope binding domains |
Torisu-Itakura et al. [100] | Melanoma | CSPG4/CD3-bispecific BiTE | Pre-clinical, in vitro | BiTe antibodies redirect the lysis of melanoma cells engaging patient-derived T cells |
Amoury et al. [101] | TNBC | CSPG4-specific single-chain mAb 9.2.27 fragment fused to MAP tau | Pre-clinical, in vitro and in vivo | Fusion construct induces cytotoxic effects on TNBC cancer cells and the inhibition of tumor growth |
Chekenya et al. [58] | GB | CSPG4 sh-induced KD | Pre-clinical, in vitro and in vivo | CSPG4 is associated with multi-drugs resistance and tumor growth through α3β1 integrin/PI3 K signaling |
Yu et al. [102] | Melanoma | mAb 225.28 | Pre-clinical, in vitro | mAb treatment enhances the in vitro efficacy of Braf-mediated inhibition of cancer cells |
Mittelman et al. [104] | Melanoma | Vaccination with mouse anti-idiotypic mAb MF11-30 | Clinical, in vivo | MF11-30 is safe, immunogenic and induces minor response in stage IV melanoma patients |
Mittelman et al. [105] | Melanoma | Vaccination with mouse anti-idiotypic mAb MK2-23 | Clinical, in vivo | MK2-23 is immunogenic and induces survival prolongation and metastasis regression |
Wang et al. [106] | Melanoma | Vaccination with mouse anti-idiotypic mAb MK2-23 conjugated to IL-2 | Pre-clinical, in vivo | IL-2 conjugation to MK2-23 is critical to induce an effective humoral and cellular response |
Riemer et al. [107] | Melanoma | Vaccination with mAb 225.28-selected mimotope fused with streptococcal ABP | Pre-clinical, in vitro and in vivo | Mimotope is immunogenic and reactive against CSPG4+ melanoma cells |
Wagner et al. [108] | Melanoma | Vaccination with mAb 225.28-selected mimotope fused with tetanus toxoid | Pre-clinical, in vitro and in vivo | Mimotope is immunogenic and reactive against CSPG4+ melanoma cells |
Luo et al. [109] | Melanoma | Vaccination with peptide P763.74 mimicking CSPG4 | Pre-clinical, in vitro and in vivo | P763.74 inhibits melanoma cells migration through immunological and non-immunological mechanisms |
Melanoma | DNA electrovaccination | Pre-clinical, in vitro and in vivo | Anti-CSPG4 DNA vaccination is immunogenic and clinically effective in canine melanoma patients |